PVLA
Palvella Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Price History
Fundamentals
| Market Cap | $1.98B |
| P/E Ratio (TTM) | - |
| Forward P/E | -20.28 |
| EPS (TTM) | $-4.17 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -34.25% |
| Debt/Equity | 8.77 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $229.60 |
| Analysts | 15 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 71.9 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $161.38 |
| 52-Week Low | $23.76 |
| 50-Day Avg | $120.57 |
| 200-Day Avg | $100.93 |
| Avg Volume | 262.2K |
| Volume | 413.2K |
Performance Analysis
BULLISHPVLA shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:28 UTC
Back to Screener Export Report